MDExam
US$ 21.92
glp 1 drugs zepbound Menopause Hormone Therapy May Boost GLP-1 Drug Benefits Is Zepbound a Semaglutide GLP-1?
Description
North America dominated the global GLP-1 receptor agonist market share by 76% in 2025
Rubio, N
10.2337/dc14-1142 [DOI] [PubMed] [Google Scholar] 80.Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, et al
Countries such as Germany, France, and the UK play a key role in driving demand, supported by robust healthcare expenditure and access to cutting-edge medical technologies
